Glenmark opts for Horizon’s gene edited cell lines

By Ben Hargreaves contact

- Last updated on GMT

(Image: Getty/Milkos)
(Image: Getty/Milkos)

Related tags: Glenmark Pharmaceuticals, Horizon Discovery, Cell line, Monoclonal antibodies

Glenmark signs a full commercial license to utilize Horizon’s gene edited CHO cell lines to be added to the former’s biomanufacturing process.

The agreement sees Glenmark Pharmaceuticals gain access to Horizon Discovery’s glutamine synthetase knockout Chinese Hamster Ovary (CHO) K1 cell line.

Regarding its decision to opt for Horizon’s technology, Glenmark confirmed that the cell lines were able to deliver clones with ‘high levels of productivity’ and a ‘favorable stability’ when compared with its previous system during testing.

Martin Bertschinger, deputy director of cell sciences at Glenmark, said, “Incorporating this technology into our biomanufacturing processes enhances our ability to efficiently generate high quality cell lines.”

The Indian company has been scaling up its production of biologics in recent years, which has seen it open a facility in La Chaux-de-Fonds​, Switzerland, and to add second single-use production line​ to manufacture monoclonal antibodies (mAbs) and bispecific antibodies.

Glenmark holds four mAbs within its clinical pipeline, with the drug candidates being investigated within oncology and immunology.

Dirk Gewert, business unit director at Horizon Discovery, confirmed that the technology had been used by other companies to progress their clinical candidates towards commercialization.

“This proprietary solution has now been licensed to over 50 companies globally, which, together with a number of confirmed investigational new drug filings for products expressed in the cells, demonstrates increasing industry acceptance,”​ he commented.

Related topics: Pipelines, Bio Developments, Cell lines

Related news

Show more

Related products

show more

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Cultivation of 3D Cell Aggregates in Perfusion

Cultivation of 3D Cell Aggregates in Perfusion

Eppendorf for Bioprocess – Solutions that grow with you | 17-Sep-2018 | Application Note

3D cell aggregates are of great interest for applications like disease modeling and manufacturing of stem cell-based products. Read more about the cultivation...

Nifty Biosimilar

Nifty Biosimilar

UGA Biopharma | 13-Mar-2018 | Research Study

Aflibercept (Zaltrap®) is a recombinant fusion protein with complex post-translational modifications. Therefore deep understanding of biosimilar development...

Related suppliers

Follow us


View more